IMRIS announces development program for MR guided radiation and interventional applications
The collaboration signals the entry of IMRIS into the field of image guided radiation therapy, expanding on its existing expertise in neurosurgery. IMRIS, a market leader in the field of advanced surgical MR imaging and UHN, with its specialized knowledge in imaging and radiation therapy, will focus on the creation of innovative technologies for radiation therapy. The clinical setting for research and testing of technologies will be Princess Margaret Hospital (PMH), UHN’s world-leading cancer research hospital. The IMRIS 3T movable MR will be installed at PMH to enable the development of new approaches to radiation therapy using active MR guidance.
The goals of the collaboration include the development of new technologies, the establishment of clinical workflows and the validation of the benefits of MR guided radiation therapy technology to both the patient and the health system. Planned applications include the integration of the IMRIS technology with external beam radiation therapy, MR guided biopsies and brachytherapy of the prostate.
“We are extremely pleased to be working with a recognized leader in cancer treatment and research,” said
About Princess Margaret Hospital:
Princess Margaret Hospital has achieved an international reputation as a global leader in the fight against cancer and is considered one of the top comprehensive cancer treatment and research centres in the world. Located in
IMRIS (TSX: IM) is a global leader in providing fully integrated, advanced surgical imaging solutions. The company’s flagship product, IMRISneuro, utilizes patented technology that allows a high field MRI scanner to be moved in to the operating room on demand, providing imaging during the surgical procedure without compromising patient safety. This unique and innovative system has been validated by leading surgeons for use in world-class neuroscience centers.
For more information, visit www.imris.com
SOURCE IMRIS Inc.